Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)
Inhibrx Biosciences (INBX) reported Free Cash Flow of -$30.1 million for Q4 2025, up 31.13% year-over-year from -$23.0 million in Q4 2024, and up 10.97% quarter-over-quarter from -$33.8 million in Q3 2025.
Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Free Cash Flow data on file, last reported at -$30.1 million in Q4 2025.
- Free Cash Flow for Q4 2025 came in at -$30.1 million, up 31.13% year-over-year; the trailing twelve-month figure through Dec 2025 was -$129.8 million (up 34.1% YoY), and the FY2025 annual result was -$129.8 million, up 34.1% from the prior year.
- Free Cash Flow advanced to -$30.1 million in Q4 2025 per INBX's latest filing, from -$33.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$30.0 million in Q2 2025 and troughed at -$63.4 million in Q1 2024.
- A 3-year average of -$44.2 million and a median of -$39.8 million in 2024 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 47.65% in 2025 and fell as far as 3.61% in 2025.
- A 3-year view of Free Cash Flow shows it stood at -$60.3 million in 2023, then increased by 27.42% to -$43.7 million in 2024, then surged by 31.13% to -$30.1 million in 2025.
- Business Quant data shows INBX's Free Cash Flow at -$30.1 million in Q4 2025, -$33.8 million in Q3 2025, and -$30.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | -30.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.12 Mn |
| Dec 31, 2025 | -30.12 Mn |
| Sep 30, 2025 | -33.83 Mn |
| Sep 30, 2025 | -33.83 Mn |
| Jun 30, 2025 | -29.97 Mn |
| Jun 30, 2025 | -29.97 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Dec 31, 2024 | -43.74 Mn |
| Dec 31, 2024 | -43.74 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Jun 30, 2024 | -57.26 Mn |
| Jun 30, 2024 | -57.26 Mn |
| Mar 31, 2024 | -63.36 Mn |
| Mar 31, 2024 | -63.36 Mn |
| Dec 31, 2023 | -60.26 Mn |
| Dec 31, 2023 | -60.26 Mn |
| Sep 30, 2023 | -55.06 Mn |
| Sep 30, 2023 | -55.06 Mn |